This content is machine translated From chemotherapy to immunotherapy Current system therapy in metastatic non-small cell lung cancer. Detailed molecular diagnosis is now mandatory for non-small cell lung cancer (NSCLC). In the presence of a driver mutation, the corresponding tyrosine kinase inhibitor should be used in the first…
View Post 7 min This content is machine translated New therapies Progress in metastatic malignant melanoma New insights in tumor biology and immunology as well as in molecular pathology have rapidly driven the development of immunomodulatory antibodies and so-called “targeted” therapeutics [1]. This makes the therapy…
